Skip to main content

Table 1 Clinical impact summary

From: Clinical utility of custom-designed NGS panel testing in pediatric tumors

Tumor type Number of patients Any clinical Impact Diagnostic impact Prognostic impact Potential change to therapy Potential Germline alteration
Tier 1 and 2 Result changed diagnosis Tier 1 and 2 Change based on prognosis Targeted therapy
CNS 96 87 (90.6%) 87 (90.6%) 3 (3.1%) 80 (83.3%) 75 (78.1%) 5 (5.2%) 26 (27.1%)
Leukemia/lymphoma 124 110 (88.7%) 104 (83.9%) 4 (3.2%) 65 (52.4%) 22 (17.7%) 7 (5.7%) 8 (6.5%)
Solid (non-CNS) 147 92 (62.6%) 73 (49.7%) 5 (3.4%) 36 (24.5%) 34 (23.1%) 32 (21.8%) 37 (25.2%)
Total 367 289 (78.7%) 264 (71.9%) 12 (3.3%) 181 (49.1%) 131 (35.7%) 44 (12.0%) 71 19.3%)